Skip to main content
. 2010 Nov 24;96(2):E368–E372. doi: 10.1210/jc.2010-2070

Fig. 1.

Fig. 1.

Survival characteristics of patients on the studied trials vs. genetic variants in ERα and CYP19. A, PFS of docetaxel plus thalidomide in patients carrying only ERα A>G variants (5.8 months; n = 11) and those carrying at least a single wild-type allele (8.3 months; n = 37, P = 0.015). B, PFS of combined docetaxel-based trials in patients carrying only ERα T>C variants (5.7 months; n = 26) and those carrying at least a single wild-type allele (8.8 months; n = 81; P = 0.036). C, Patients carrying only ERα A>G variants (4.8 months; n = 20) and those carrying at least a single wild-type allele (8.8 months; n = 88; P = 0.0012). D, Survival after docetaxel treatment of combined docetaxel trials in patients who were >70 years of age carrying CYP19 variant alleles (15.7 months; n = 5) and those carrying only wild-type alleles (26.3 months; n = 42; P = 0.041). E, PFS of docetaxel-based trials in individuals who were not obese (BMI < 30) carrying only ERα A>G variant alleles (3.2 months; n = 9) and those carrying at least one copy of a wild-type allele (6.7 months, n = 40; P = 0.0078). F, PFS of thalidomide monotherapy in patients carrying ERα T>C homozygous and heterozygous genotypes (5.3 and 3.1 months, respectively; n = 9 and n = 23, respectively) and those carrying wild-type alleles (1.8 months; n = 8; P = 0.040).